Hui Guo

Hui Guo

Auto-generated profile, based on publicly available information

Hui Guo

State Key Laboratory of RNA Science and Engineering, State Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences 1 , Beijing

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in The EMBO Journal
Verified
Journal Article
Closed access
HGHui Guo
Hui Guo
JZJiahang Zhang
Jiahang Zhang
ZHIMIN JiangZHIMIN Jiang
ZHIMIN Jiang
XZXiaoxiao Zhu
Xiaoxiao Zhu
JYJing Yang
Jing Yang
ZFZusen Fan
Zusen Fan

1 March 2018 in Medicine
Verified
Journal Article
Open access
FLFaping Li
Faping Li
HGHui Guo
Hui Guo
HQHeping Qiu
Heping Qiu
SLshukun liu
shukun liu
KWKaixuan Wang
Kaixuan Wang
YHYuchuan Hou
Yuchuan Hou
Radiotherapy is a reliable method to cure cervical cancer patients, but it could cause serious urological complications after the treatment due to the anatomical location of the cervix. The main purpose of this retrospective analysis is to study the incidence, latency, and therapeutic efficacy of urological complications caused by radical hysterectomy with postoperative radiotherapy or radiotherapy alone in patients with cervical cancer. A retrospective analysis was conducted on patients with cervical cancer who received radical hysterectomy with postoperative radiotherapy or radiotherapy alone at the First Hospital of Jilin University between January 2010 and May 2016. The urological complications were confirmed by clinical manifestation, ultrasound, computed tomography (CT), nuclear scintigraphy, and assessment of renal function. All the patients with urological complications received conventional treatment, including conservative, electrosurgery, ureteral stents, nephrectomy, and neoplasty. The onset time of radiation injury symptoms was confirmed according to the medical history and follow-up. The surveillance for the therapeutic effects for these complications was accomplished by cystoscopy, imaging, and laboratory assessment. The overall rate of urological complications after treatment was 3.26%, comprising 2.12% ureteral obstruction, 0.98% radiocystitis, and 0.16% vesicovaginal fistula. The incidence of ureteral obstruction in patients treated with radical hysterectomy with postoperative radiotherapy and radiotherapy alone was not statistically significant (2.18% vs 1.59%, P > .05). The median onset time of radiocystitis and ureteral obstruction was 10 months (0–75 months) and 12 months (2–66.3 months), respectively. The onset time of vesicovaginal fistula was 3.5 months. After the appropriate treatment, the majority of the complications were under control. The incidence of urological complications is acceptable. There was no statistical difference in the risk between patients treated with radical hysterectomy with postoperative radiotherapy and radiotherapy alone. The latency period between radiotherapy and the manifestation of urological complications may be relatively long. So it is crucial to underline long-term follow-up after radiotherapy. The majority of urological complications were alleviated after symptomatic treatment and the patients with cervical cancer achieved long-term remissions or cures.

22 August 2025 in Science Advances
Verified
Journal Article
Open access
YXYuwei Xu
Yuwei Xu
ZXZhen Xiong
Zhen Xiong
PZPeikang Zhang
Peikang Zhang
RWRunyuan Wu
Runyuan Wu
CLCunzhen Li
Cunzhen Li
ZFZusen Fan
Zusen Fan
Innate lymphoid cells (ILCs) play critical roles in innate immunity, epithelial barrier protection, and tissue homeostasis. However, the maintenance machinery of intestinal tissue residency of ILCs remains elusive. Here, we show that gut microbiota is necessary for the maintenance of intestinal tissue residency of ILCs. Microbiota metabolite taurodeoxycholic acid (TDCA) binds to P2Y10 receptor on ILCs to initiate downstream Ca 2+ and RhoA signaling pathways. TDCA-P2Y10 engagement induces Zfp414 transcription to prime expression of CD69 and integrin αE on ILCs, leading to intestinal residency of ILCs. Moreover, decreased levels of TDCA or P2Y10 deficiency abrogates the intestinal residency of ILCs, resulting in severer intestinal inflammation. Of note, TDCA administration can enhance intestinal tissue residency of ILCs and promote protection against intestinal inflammation. Thus, TDCA might be used as a potential drug to treat patients with inflammatory bowel disease.

29 November 2018 in Blood
Verified
Journal Article
Open access
YYYixin Yao
Yixin Yao
YLYang Liu
Yang Liu
HGHui Guo
Hui Guo
MAMakhdum Ahmed
Makhdum Ahmed
SBShabnam Bhuiyan
Shabnam Bhuiyan
MWMichael Wang
Michael Wang
Introduction: Cancer cells exhibit dramatic alterations in cellular metabolism, such as enhanced de novo nucleotide synthesis, to support cell growth, proliferation and survival. The abundance of the nucleotide pool as well as the level and activity of different rate-limiting enzymes belonging to the nucleotide synthetic pathway limit the maximal proliferative capacity of cells. Maintenance of an adequate pool of deoxyribonucleotide triphosphates is essential for DNA replication and DNA repair, and consequently, the genetic integrity of nuclear and mitochondrial genomes. We and others have demonstrated that mantle cell lymphoma (MCL) undergoes metabolic reprogramming to progress and develop resistance to targeted therapy; however, the contribution of de novo nucleotide synthesis to the development and progression of MCL remains poorly understood. In contrast, oncogenic Myc is demonstrated to be highly upregulated in a subset of MCL. In addition to its pro-glycolysis, pro-biogenesis and pro-tumor growth functions, oncogenic levels of Myc induce the expression of multiple genes involved in the nucleotide biosynthetic pathway (e.g., IMPDH2, CTPS1, and CAD). Myc-induced glutamine metabolism also increases the abundance and activity of different rate-limiting enzymes that produce the molecular precursors required for de novo nucleotide synthesis. The γ-nitrogen amide group of glutamine is an indispensable donor of nitrogen for de novo synthesis of both nucleobases purine and pyrimidine. Here, we hypothesize that a subset of MCL depends on de novo nucleotide synthesis for anabolic cell growth and cancer progression due to aberrant Myc expression and Myc-induced glutaminolysis. Methods: Primary MCL biopsy, apheresis, and blood specimens as well as MCL cell lines were utilized for metabolic and functional analyses. Liquid Chromatography Mass Spectrometry (LC-MS) metabolomics was employed to measure the steady-state level of metabolites. Western-blotting and real-time qPCR were utilized determine protein and gene expression levels. BrdU incorporation and the Cell-Trace Violet Cell Proliferation Assay were employed to assess DNA synthesis and cell proliferation. Cell viability was measured with the Cell Titer-Glo Cell Viability Assay. Pharmacological agents were employed to inhibit either de novo nucleotide synthesis or glutaminolysis. Results: Metabolomics profiling of steady-state levels of intracellular metabolites showed significant increases in N-carbamoyl aspartate/dihydroorotate and 5-phosphoribosyl-1-pyrophosphate (PRPP), which are critical intermediates in de novo pyrimidine and purine synthesis, respectively, as well as CTP, dUTP, dCTP, in a subset of MCL, indicating remarkably upregulated de novo nucleotide synthesis. The protein and mRNA levels of c-Myc and its target genes involved in the metabolism of nucleotides (IMPDH2, CTPS1, CAD) were significantly increased. Inhibition of pyrimidine synthesis with DON (6-diazo-5-oxo-L-norleucine), a CTPS1 inhibitor, dramatically reduced the pool of pyridine nucleotides, leading to remarkable apoptosis and halted cell proliferation of a subset of MCL cell lines. Consistent with c-Myc overexpression, increased glutamine uptake was also observed in a subset of MCL cell lines. Glutamine deprivation or pharmacological inhibition of glutamine metabolism showed a similar effect on the inhibition of pyrimidine synthesis as DON (6-diazo-5-oxo-L-norleucine), manifested by a significant reduction of pyrimidine nucleoside triphosphate levels, a dramatic increase in apoptosis, and retarded cell proliferation of a subset of MCL cell lines. Conclusions: Our preliminary results indicate that de novo nucleotide synthesis is upregulated in a subset of MCL with aberrant c-Myc expression. The expression of genes involved in nucleotide metabolism as well as glutaminolysis is also elevated in these cancer cells. Disruption of de novo nucleotide synthesis or glutaminolysis induces apoptosis and suppresses proliferation of a subset of MCL. Myc does not possess enzymatic activity and is considered "undruggable"; therefore, the inhibition of Myc target genes such as those involved in de novo nucleotide synthesis and glutaminolysis presents a promising alternative approach. Taken together, MCL dependency on de novo nucleotide synthesis may represent a metabolic vulnerability for targeted therapy for MCL.

26 December 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
CLCunzhen Li
Cunzhen Li
ZXZhen Xiong
Zhen Xiong
DKDeyuan Kong
Deyuan Kong
YXYuwei Xu
Yuwei Xu
RWRunyuan Wu
Runyuan Wu
ZFZusen Fan
Zusen Fan
Paneth cells secrete antimicrobial peptides (AMPs) to modulate composition of gut microbiota and host defense. AMPs are typically packaged into dense core vesicles (DCVs) and secreted into the intestinal lumen. However, the mechanisms underlying DCV biogenesis and secretion are still elusive. Here we identified that ERAdP was highly expressed in Paneth cells that acted as a sensor for a bacterial second messenger c-di-AMP. ERAdP deficiency caused impaired DCV biogenesis and dysfunction of Paneth cells. Mechanistically, by sensing c-di-AMP, ERAdP interacted with NLRP6 and further recruited ANXA2 onto the DCV membrane in Paneth cells. The ERAdP–NLRP6–ANXA2 complex facilitated DCV biogenesis, which enhanced antibacterial ability of intestines. Disruption of ERAdP–NLRP6–ANXA2 axis led to loss of DCVs in Paneth cells and increased susceptibility to bacterial infection. Of note, ERAdP–NLRP6–ANXA2 proteins were lowly expressed in IBD patients, and c-di-AMP treatment enhanced antibacterial capacity in antibiotic-treated mice. Our findings reveal that c-di-AMP stimulation might provide a potential therapeutic strategy for infectious disease and gut inflammation.

1 April 2011 in The Journal of Immunology
Verified
Journal Article
Open access
GQGuilin Qiao
Guilin Qiao
HYHaiyan Ying
Haiyan Ying
HGHui Guo
Hui Guo
BCBohao Chen
Bohao Chen
XZXiangdong Zhu
Xiangdong Zhu
JZJian Zhang
Jian Zhang
Casitas-B-lineage lymphoma protein-b (Cbl-b), an E3 ubiquitin ligase, belongs to the Cbl family. Recent studies indicate that Cbl-b emerges as a gatekeeper that controls the activation threshold of the antigen receptor and maintains the balance between tolerance and autoimmunity. However, the role of Cbl-b in T helper (Th) cell differentiation remains unknown. In this study, we show that Cbl-b deficiency selectively results in a biased Th2 differentiation in vitro. Furthermore, using a mouse model of asthma, we find that the absence of Cbl-b results in severe airway inflammation which associates with stronger Th2 responses including elevated IL-4, IL-5, and IL-13, and accumulation of eosinophils in bronchoalveolar lavage (BAL) fluid and higher titers of IgE in the serum. At the molecular level, Cbl-b selectively associates with Stat-6 upon IL-4 ligation, and targets Stat-6 for K48-linked polyubiquitination and subsequently degradation in the proteasome. These processes are heightened in the presence of TCR/CD28 costimulation. IL-4-induced Cbl-b-Stat6 association requires Cbl-b TKB domain, whereas TCR/CD28-induced Cbl-b-Stat6 interaction is mediated by tyrosine residues of Cbl-b and SH2 domain of Stat6. Therefore, we have discovered a previously uncharacterized function of Cbl-b in Th2 cell differentiation that may serve as an important therapeutic target for allergic diseases including asthma.